Objective: To investigate the influence of hyperbaric oxygen combined with psychotropic drugs on serum neurotransmitter and cytokine contents in patients with post-stroke depression. Methods: A total of 62 patients wi...Objective: To investigate the influence of hyperbaric oxygen combined with psychotropic drugs on serum neurotransmitter and cytokine contents in patients with post-stroke depression. Methods: A total of 62 patients with post-stroke depression who were treated in the hospital between January 2015 and February 2017 were divided into routine group (n=31) and hyperbaric oxygen group (n=31) by random number table method. Routine group received antidepressant therapy, hyperbaric oxygen group received hyperbaric oxygen combined with antidepressant therapy, and the therapies lasted for 8 weeks. The differences in the serum contents of monoamine neurotransmitters, inflammatory factors and oxidative stress indexes were compared between the two groups before and after treatment. Results: There was no statistically significant difference in serum levels of monoamine neurotransmitters, inflammatory factors and oxidative stress indexes between the two groups before treatment. After 8 weeks of treatment, serum monoamine neurotransmitters NE, 5-HT and DA contents of hyperbaric oxygen group were higher than those of routine group;serum inflammatory factors IL-1, IL-6, IL-8 and hs-CRP contents were lower than those of routine group;serum oxidative stress indexes LHP and MDA contents were lower than those of routine group whereas CAT and GSH-Px contents were higher than those of routine group. Conclusion:Hyperbaric oxygen combined with psychotropic drug therapy can effectively increase the expression of monoamine neurotransmitters and balance the homeostasis in patients with post-stroke depression.展开更多
目的分析利拉鲁肽致胰腺炎的临床特点,为临床合理用药提供参考。方法计算机检索中国知网、维普网、万方数据、PubMed、Web of Science和Medline数据库,收集利拉鲁肽致胰腺炎的个案报道,检索时限为从建库起至2022年12月31日,描述性分析...目的分析利拉鲁肽致胰腺炎的临床特点,为临床合理用药提供参考。方法计算机检索中国知网、维普网、万方数据、PubMed、Web of Science和Medline数据库,收集利拉鲁肽致胰腺炎的个案报道,检索时限为从建库起至2022年12月31日,描述性分析患者人口学特征、用药情况、临床表现、干预与转归等。结果共纳入文献17篇,涉及17例患者,其中男性7例、女性10例,年龄为25~75岁;均有用药指征,包括2型糖尿病14例,肥胖或超重3例;其中单一用药5例,合并用药12例。17例患者胰腺炎的发生时间均为利拉鲁肽用药后1 d~11个月,大多出现在6个月以内(14例);主要临床表现包括腹痛、恶心和呕吐等。诊断为胰腺炎后,16例停用利拉鲁肽,其中1例未予其他干预,15例予以对症治疗,16例患者症状均缓解,但2例在利拉鲁肽停用数周后再次发生胰腺炎,且均为重度胰腺炎,1例患者再次应用利拉鲁肽后胰腺炎再次发生。关联性评价结果显示,1例为“肯定”,4例为“可能”,其余患者为“很可能”。结论利拉鲁肽致胰腺炎多发生在用药6个月内,多为轻度、中重度,但也可能出现严重甚至致命的病例。临床在应用利拉鲁肽时,应定期监测患者胰酶水平并密切观察其临床表现,若出现疑似利拉鲁肽诱发的胰腺炎,应尽早停药并给予对症治疗。展开更多
文摘Objective: To investigate the influence of hyperbaric oxygen combined with psychotropic drugs on serum neurotransmitter and cytokine contents in patients with post-stroke depression. Methods: A total of 62 patients with post-stroke depression who were treated in the hospital between January 2015 and February 2017 were divided into routine group (n=31) and hyperbaric oxygen group (n=31) by random number table method. Routine group received antidepressant therapy, hyperbaric oxygen group received hyperbaric oxygen combined with antidepressant therapy, and the therapies lasted for 8 weeks. The differences in the serum contents of monoamine neurotransmitters, inflammatory factors and oxidative stress indexes were compared between the two groups before and after treatment. Results: There was no statistically significant difference in serum levels of monoamine neurotransmitters, inflammatory factors and oxidative stress indexes between the two groups before treatment. After 8 weeks of treatment, serum monoamine neurotransmitters NE, 5-HT and DA contents of hyperbaric oxygen group were higher than those of routine group;serum inflammatory factors IL-1, IL-6, IL-8 and hs-CRP contents were lower than those of routine group;serum oxidative stress indexes LHP and MDA contents were lower than those of routine group whereas CAT and GSH-Px contents were higher than those of routine group. Conclusion:Hyperbaric oxygen combined with psychotropic drug therapy can effectively increase the expression of monoamine neurotransmitters and balance the homeostasis in patients with post-stroke depression.
文摘目的分析利拉鲁肽致胰腺炎的临床特点,为临床合理用药提供参考。方法计算机检索中国知网、维普网、万方数据、PubMed、Web of Science和Medline数据库,收集利拉鲁肽致胰腺炎的个案报道,检索时限为从建库起至2022年12月31日,描述性分析患者人口学特征、用药情况、临床表现、干预与转归等。结果共纳入文献17篇,涉及17例患者,其中男性7例、女性10例,年龄为25~75岁;均有用药指征,包括2型糖尿病14例,肥胖或超重3例;其中单一用药5例,合并用药12例。17例患者胰腺炎的发生时间均为利拉鲁肽用药后1 d~11个月,大多出现在6个月以内(14例);主要临床表现包括腹痛、恶心和呕吐等。诊断为胰腺炎后,16例停用利拉鲁肽,其中1例未予其他干预,15例予以对症治疗,16例患者症状均缓解,但2例在利拉鲁肽停用数周后再次发生胰腺炎,且均为重度胰腺炎,1例患者再次应用利拉鲁肽后胰腺炎再次发生。关联性评价结果显示,1例为“肯定”,4例为“可能”,其余患者为“很可能”。结论利拉鲁肽致胰腺炎多发生在用药6个月内,多为轻度、中重度,但也可能出现严重甚至致命的病例。临床在应用利拉鲁肽时,应定期监测患者胰酶水平并密切观察其临床表现,若出现疑似利拉鲁肽诱发的胰腺炎,应尽早停药并给予对症治疗。
